(NASDAQ: TNGX) Tango Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.63%.
Tango Therapeutics's earnings in 2026 is -$123,720,000.On average, 15 Wall Street analysts forecast TNGX's earnings for 2026 to be -$223,577,347, with the lowest TNGX earnings forecast at -$237,942,950, and the highest TNGX earnings forecast at -$203,597,018. On average, 14 Wall Street analysts forecast TNGX's earnings for 2027 to be -$260,132,074, with the lowest TNGX earnings forecast at -$295,776,306, and the highest TNGX earnings forecast at -$203,597,018.
In 2028, TNGX is forecast to generate -$281,022,899 in earnings, with the lowest earnings forecast at -$394,919,202 and the highest earnings forecast at -$192,974,565.